Browsing by Subject "seizures"
- Results Per Page
- Sort Options
Item Open Access Adrenoceptor blockade modifies regional cerebral blood flow responses to hyperbaric hyperoxia: Protection against CNS oxygen toxicity.(Journal of applied physiology (Bethesda, Md. : 1985), 2018-07-19) Gasier, Heath G; Demchenko, Ivan T; Zhilyaev, Sergei Yu; Moskvin, Alexander N; Krivchenko, Alexander I; Piantadosi, Claude AExposure to extreme-hyperbaric oxygen (HBO2), > 5-6 atmospheres absolute (ATA), produces baroreflex impairment, sympathetic hyperactivation, hypertension, tachycardia, and cerebral hyperemia, known as Phase II, culminating in seizures. We hypothesized that attenuation of the effects of high sympathetic outflow would preserve regional cerebral blood flow (rCBF) and protect against HBO2-induced seizures. To explore this possibility, we tested four adrenoceptor antagonists in conscious and anesthetized rats exposed to HBO2 at 5 and 6 ATA, respectively: phentolamine (nonselective α1 and 2), prazosin (selective α1), propranolol (nonselective β1 and 2) and atenolol (selective β1). In conscious rats, 4 drug-doses were administered to rats prior to HBO2 exposures, and seizure latencies were recorded. Drug-doses that provided similar protection against seizures were administered before HBO2 exposures in anesthetized rats to determine the effects of adrenoceptor blockade on mean arterial pressure, heart rate, rCBF and EEG spikes. All four drugs modified cardiovascular and rCBF responses in HBO2 that aligned with epileptiform discharges, but only phentolamine and propranolol effectively increased EEG spike latencies by ~20 and 36 min, respectively. When phentolamine and propranolol were delivered during HBO2 at the onset of phase II, only propranolol led to sustained reductions in heart rate and rCBF, preventing the appearance of epileptiform discharges. The enhanced effectiveness of propranolol may extend beyond β-adrenoceptor blockade, i.e. membrane stability and reduced metabolic activity. These results indicate that adrenoceptor drug pre-treatment will minimize the effects of excessive sympathetic outflow on rCBF and extend HBO2 exposure time.Item Open Access MicroRNA-29 is an essential regulator of brain maturation through regulation of CH methylation.(Cell reports, 2021-04) Swahari, Vijay; Nakamura, Ayumi; Hollville, Emilie; Stroud, Hume; Simon, Jeremy M; Ptacek, Travis S; Beck, Matthew V; Flowers, Cornelius; Guo, Jiami; Plestant, Charlotte; Liang, Jie; Kurtz, C Lisa; Kanke, Matt; Hammond, Scott M; He, You-Wen; Anton, ES; Sethupathy, Praveen; Moy, Sheryl S; Greenberg, Michael E; Deshmukh, MohanishAlthough embryonic brain development and neurodegeneration have received considerable attention, the events that govern postnatal brain maturation are less understood. Here, we identify the miR-29 family to be strikingly induced during the late stages of brain maturation. Brain maturation is associated with a transient, postnatal period of de novo non-CG (CH) DNA methylation mediated by DNMT3A. We examine whether an important function of miR-29 during brain maturation is to restrict the period of CH methylation via its targeting of Dnmt3a. Deletion of miR-29 in the brain, or knockin mutations preventing miR-29 to specifically target Dnmt3a, result in increased DNMT3A expression, higher CH methylation, and repression of genes associated with neuronal activity and neuropsychiatric disorders. These mouse models also develop neurological deficits and premature lethality. Our results identify an essential role for miR-29 in restricting CH methylation in the brain and illustrate the importance of CH methylation regulation for normal brain maturation.Item Open Access Use of Machine Learning and Computer Vision Methods for Building Behavioral and Electrophysiological Biomarkers for Brain Disorders(2023) Isaev, DmitryResearch on biomarkers of brain disorders is an actively developing area. Biomarkers may allow for the early detection of diseases, which is essential for early intervention and improved outcomes. Biomarkers for monitoring the changes in the patient’s state can potentially increase the efficiency of clinical trials. Digital biomarkers, which emerged in recent years, rely on applications of machine learning methods to the data gathered by low-cost sensors, often embedded in consumer devices. Digital biomarkers have the potential to provide low-cost and more objective, granular, and sensitive to change metrics than traditional clinical ratings used in assessments of neurological and neurodevelopmental disorders. On the other hand, in traditional electrophysiological methods measuring brain activity, such as electroencephalography (EEG), biomarkers historically were based on visual analysis by clinicians, classical signal processing measures, or event-related potential (ERP) technique. Search for machine learning-based EEG biomarkers is an active area of research. This dissertation aims to build novel digital behavioral and EEG-based biomarkers and outcome measures by applying machine learning to behavioral, EEG, and concurrently recorded behavioral and EEG data. Machine learning models for the detection of gaze, human face and body landmarks, and automatic speech recognition achieve good performance on publicly available datasets. However, applying these models to a new clinical dataset immediately incurs a dataset shift problem, since the conditions under which real clinical video and audio data are recorded differe from the training dataset (e.g. different video camera angles, or audio noise). Furthermore, clinical datasets are in general much smaller than those used for training such models, and there are not enough human resources in the clinical setting to perform data labeling, making re-training not feasible. Yet, the question remains – whether the predictions from pre-trained models can provide valuable insight into human behavior and neurophysiology in the clinical setting, and whether they can be a source of clinically relevant findings. In this dissertation, we first explore this question in two use cases: (1) building digital measures of caregiver-child interaction in neurodevelopmental disorders using pre-trained pose detection deep learning models; (2) creating a digital biomarker of ataxic dysarthria using pre-trained automatic speech recognition deep learning models. We show that in the first case, our method enables to distinguish different clusters of caregiver responsiveness which are associated with a child’s caregiver- and clinician-reported socialization, communication, and language abilities, thus demonstrating the feasibility of using digital measures of caregiver-child interaction in clinical trials. In the second case, we demonstrate the convergent validity of our novel biomarker with clinician-reported scores and the greater sensitivity to change than clinician-reported scores on a longitudinal dataset. Second, we propose a novel deep learning model for detecting seizures in neonates from EEG data. We demonstrate the model’s high generalizability by evaluating it on an independent dataset from another hospital and show that model by design can be applied in different facilities with different EEG hardware. This approach has the potential to be clinically validated and will allow to scale up studies of neonatal seizures by increasing the sample sizes (including data from multiple clinical centers). Finally, we turn to the problem of combining EEG and behavioral biomarkers, which can improve biomarker sensitivity, but also provide new insights into brain-behavior relationships. In the study of autism, we propose a new metric of attentional preference to social/non-social stimuli and show that not only it distinguishes between autistic and neurotypical children, but also is differently associated with brain activity as measured by EEG. Then we turn to the question of scaling up EEG and behavior studies and provide the tool that allows measuring participants’ attention to the screen during EEG recording. This tool will allow to reduce human effort and make measurements of participants’ visual attention more objective, thus scaling up data preprocessing and allowing for multi-center studies of concurrent EEG and behavior.